Dengue vaccine ‘DengiAll’ may hit Indian market by late 2027

India could see the launch of its first indigenous dengue vaccine, ‘DengiAll’, by late 2027, provided all remaining stages of testing and regulatory approval are completed successfully.

Dengue cases typically rise in India with the arrival of the monsoon, affecting large numbers of people every year. The Indian Council of Medical Research (ICMR) has said the locally developed vaccine could become available to the public before the start of the 2027 dengue season if the ongoing process proceeds as planned.

Speaking at an event in Kolkata, the ICMR Director General said the clinical trials and approval process for the indigenous dengue vaccine are progressing. However, whether the vaccine reaches the market within the projected timeframe will depend on the final trial results and approval from the regulatory authorities.

Drugmaker Panacea Biotec is developing the tetravalent dengue vaccine DengiAll in collaboration with the ICMR. The vaccine is currently undergoing Phase III clinical trials. According to the ICMR’s latest annual report, 10,335 participants are taking part in the trial across 19 centres in 18 states.

The Phase III trial is assessing the vaccine’s effectiveness against dengue, its safety profile and its ability to generate an adequate immune response. Dengue virus has four major serotypes, making protection against all four types an important consideration for an effective vaccine.

Once the trial results are analysed, regulatory approval will be required before the vaccine can be marketed. Therefore, although officials have indicated that it could become available before the 2027 dengue season, that timeframe should not yet be regarded as a firm deadline.

Meanwhile, foreign-made dengue vaccines have also received approval in India. Documents from the country’s Central Drugs Standard Control Organisation (CDSCO) show that Takeda’s tetravalent dengue vaccine received approval in July 2026. In March, a regulatory expert committee had also reviewed Phase III trial data from the Indian population and made a recommendation regarding the vaccine.

As there is no specific antiviral treatment for dengue, patients are generally treated and monitored based on their symptoms. Severe dengue can lead to various complications. As a result, the availability of a safe and effective vaccine could play an important role in reducing dengue transmission and the overall disease burden.

Source: Anandabazar Patrika